Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.